HBM contact: Dr Ivo Staijen, Dr Alexander Asam
Company status: public
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders. Aptinyx has a proven platform for discovering compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. The lead asset is undergoing two Phase 2 clinical trials in painful diabetic peripheral neuropathy as well as fibromyalgia.